SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is facing downward pressure, with community members debating whether it's losing ground to gold as a safe haven asset. Speculation is swirling around a potential announcement and its possible impact, while others point to technical charts suggesting further declines. Community members are also discussing the potential impact of macro events on Bitcoin's price.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices reach new all-time highs, fueled by trade tensions and expectations of dovish moves by the Federal Reserve. The community is actively debating whether gold's surge signals broader economic instability or if it's entering bubble territory, with some comparing it to Bitcoin's volatility. Discussions also revolve around potential pullbacks, profit-taking strategies, and the impact of central bank activity and global events.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QS is trending amid significant price volatility and high trading volume, with community discussions focused on whether recent price movements are a buying opportunity or a signal to exit. Positive sentiment stems from potential OEM partnerships and solid-state battery technology advancements, while negative sentiment centers on the company's lack of revenue and cash burn rate. Traders are closely watching for a potential short squeeze and upcoming earnings news.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending due to its volatile Nasdaq debut, marked by multiple trading halts and a wide price range. The community is actively discussing entry points, potential shorting activity, and the company's long-term prospects in the solar EV market. Despite the initial turbulence, some investors remain optimistic about Aptera's technology and future potential.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending due to significant volatility following positive Phase 3 trial results for its essential tremor treatment, though some analysts are tempering expectations. Community discussions revolve around profit-taking strategies, short selling opportunities, and potential dilution. Several traders are pointing to other bio stocks to watch.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders hedge against market uncertainty, with community members discussing potential upside driven by geopolitical tensions and economic data. Some are debating whether the recent moves signal a larger correction, while others are looking to profit from short-term volatility. The fund's movements are being closely watched amid broader concerns about market valuations and the potential impact of a government shutdown.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is seeing increased volatility as traders await an announcement, reportedly related to trade, though some community members suspect it may be related to domestic policy. Discussion revolves around potential market manipulation and directional speculation based on the content of the upcoming announcement. Concerns about bank earnings and the VIX are also contributing to bearish sentiment.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF ($GDX) is trending upwards, driven by factors such as US-China trade tensions and speculation around potential Federal Reserve rate cuts, pushing gold prices to new all-time highs. Community members are actively discussing whether to load up on call options or take profits, with some pointing to technical indicators suggesting the ETF is overbought. Broader discussions include the potential for gold to reach new price targets amid global economic uncertainty and dollar devaluation.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending downwards as the community discusses legal challenges in the UK related to talc and recent comments linking Tylenol to autism, despite denials from the company and experts. Community members are debating the impact of potential liabilities and the company's valuation, while also pointing to large options positions, potential bottom fishing opportunities, and speculation around management's response. Some traders express a long-term bullish outlook, emphasizing Kenvue's strong brand portfolio and dividend.

Terra Innovatum Global NV operates as a holding company that offers micro-reactor solutions. It engages in the development of nuclear micro modular solutions focused on clean energy. The firm's nuclear technology, the SOLO features a thermally-moderated, gas-cooled nuclear reactor core that operates with standard enrichment U235 and conventional Zircaloy-cladded UO2 fuel pellets. The company was founded on April 29, 2025 and is headquartered in Lucca, Italy.

Terra Innovatum Global N.V.

Terra Innovatum Global N.V. Ordinary shares

NKLR is trending due to recent volatility, with community members actively discussing large price swings and potential bottom levels. Some investors believe it's a buying opportunity, while others express concerns about its correlation with the rare earth sector. The upcoming ringing of the opening bell at NASDAQ is also a point of discussion.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter spiked around Invivyd on Monday after the company said its monoclonal antibodies pemivibart and VYD2311 continued to neutralize the emerging XFG variant of COVID-19 in laboratory tests.The company reported that both antibodies remained effective against XFG, which U.S. Centers for Disease Control and Prevention data and wastewater surveillance suggest is driving a rising wave of infections in the U.S.&nbsp;Similar results were shown against other circulating variants, including NB.1.8.1, LF.7.9 and LP.8.1. Invivyd said it identified no resistant strains.The data will be submitted to the U.S. Food and Drug Administration (FDA) for planned inclusion in the fact sheet for pemivibart, which is currently authorized under emergency use for pre-exposure prevention of COVID-19 in certain immunocompromised patients.The update follows news last week that Invivyd reached alignment with the FDA on a streamlined regulatory pathway for VYD2311.&nbsp;In a recent Type C meeting, the agency advised that a single Phase 2/3 randomized, placebo-controlled trial with a relatively modest number of symptomatic COVID-19 cases could support a biologics license application.&nbsp;Invivyd said it plans to test two doses of VYD2311 and has clinical supply on hand.Infections are growing or likely growing in 34 states, with wastewater data showing high or very high viral levels in 12 states, the company said, citing CDC forecasts.&nbsp;Invivyd said the structural target of its antibodies has remained stable across major variants since Omicron BA.2, supporting continued neutralization activity.On Stocktwits, retail sentiment for Invivyd was ‘bullish’ amid a 175% surge in 24-hour message volume.One user noted they had seen Invivyd fall to $0.48 before quickly rebounding above $1, adding that good timing was the only way to make money with the stock.&nbsp;<stembedurl>https://stocktwits.com/Jack696/message/625670790</stembedurl>Another user said they had added to their position at $0.61.<stembedurl>https://stocktwits.com/alexx013/message/625643913</stembedurl><a href="https://stocktwits.com/symbol/IVVD">Invivyd’s stock</a> has risen 31% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Invivyd’s (IVVD) stock has risen 31% so far in 2025. (Photo credit: Getty Images)

Retail Chatter Surges Around Invivyd After Data Show Pemgarda Neutralizes XFG COVID-19 Variant

The company also recently aligned with the FDA on a streamlined path to potential approval for its next-generation antibody VYD2311.

Equity

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -200.00% and -23.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of +17.95% and +57.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Retail buzz around Invivyd Inc. spiked on Monday after it revealed its launch of a discovery program to create a measles-specific monoclonal antibody.&nbsp;Healthcare providers managing measles patients and outbreak situations contacted Invivyd to explore access to its prospective medicine since no approved treatments or post-exposure prophylaxis options exist for measles.Invivyd shares surged 29.7% on Monday to close at $0.84.Currently, clinicians lack numerous treatment options for managing measles cases.&nbsp;Children who have contracted measles receive high-dose Vitamin A to aid their recovery process, especially when their bodies lack Vitamin A.&nbsp;While high-dose Vitamin A therapy helps treat measles in children who have a deficiency of the vitamin, it shows potential liver toxicity and remains underutilized.&nbsp;Human donor-derived pooled plasma immune globulin (IVIG) is a mix of different antibodies from several donors that hasn't been officially approved, and its inconsistent makeup makes it less reliable for widespread use.Measles vaccines stand as the best protective measure available, yet their effectiveness diminishes because some populations fail to access or refuse them, leaving unprotected gaps after exposure to the virus.&nbsp;The latest research indicates that diseases like measles, which were previously under control, could reemerge and lead to serious outcomes such as pneumonia, encephalitis,&nbsp; and long-lasting immunological consequences.The monoclonal antibody discovery program of Invivyd would grow its portfolio, which presently contains next-generation treatments for COVID-19, respiratory syncytial virus (RSV), and influenza.&nbsp;Retail sentiment around Invivyd turned ‘extremely bullish’, with a 4,800% spike in 24-hour message volume.&nbsp;Some users expressed confidence that the stock could reach multiple dollars, while others pointed to monoclonal antibodies as the “future of medicine.”<stembedurl>https://stocktwits.com/trader2sde/message/614373951</stembedurl><stembedurl>https://stocktwits.com/TheFnFortune/message/614327973</stembedurl>The stock has risen 74.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’

Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options. 

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here.

Investors could consider this penny stock after its COVID-19 antibody breakthrough sent shares soaring, and analysts see massive triple-digit gains ahead.

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF) and Invivyd (IVVD)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals Ltd. (TLPPF Research Report) and Invivyd...

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Invivyd Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

IVVD
Invivyd Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IVVD News

IVVDInvivyd Inc